Autologous Bone Marrow Transplantation for CML in Which Retroviral Markers Are Used to Discriminate Between Relapse Which Arises from Systemic Disease Remaining after Preparative Therapy Versus Relapse due to Residual Leukemia Cells in Autologous Marrow: A Pilot Trial. The University of Texas M.D. Anderson Cancer Center
- 1 December 1991
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 2 (4), 359-376
- https://doi.org/10.1089/hum.1991.2.4-359
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Marrow Transplantation for the Treatment of Chronic Myelogenous LeukemiaAnnals of Internal Medicine, 1986
- Cyclophosphamide in solid tumorsCancer Treatment Reviews, 1975
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesEuropean Journal of Cancer (1965), 1975